Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

Black Diamond Therapeutics slashes workforce by 30% while discontinuing development of BDTX-189

By Brian Buntz | April 26, 2022

Black Diamond Therapeutics

Precision oncology firm Black Diamond Therapeutics (Nasdaq:BDTX) has announced a restructuring plan to free up cash to prioritize the development of BDTX-1535 and BDTX-4933.

The company plans on trimming nearly one-third of its workforce.

BDTX shares ticked up about 1% to $2.75 after announcing the news yesterday but fell 4% today to $2.64.

According to the company, the reorganization could provide sufficient cash runway to last until the third quarter of 2024.

“In order to increase our operational efficiency and execute on our mission, we have made the difficult decision to reduce our workforce by approximately 30%,” said David Epstein, Black Diamond Therapeutics CEO, in a press release.

The company is also halting development work on BDTX-189. This drug candidate would have potentially been indicated for advanced breast cancer, biliary cancer, male breast cancer, non-small cell lung cancer, ovarian cancer and solid tumors.

BDTX-189 is an orally available, irreversible small molecule inhibitor.

When announcing its Q4 results in mid-March, Black Diamond Therapeutics said it anticipated announcing further guidance related to the program in 2022.

Black Diamond will continue to enroll subjects in the safety expansion cohort of the Phase 1 study associated with BDTX-189 but halt the development of the broader program, given changes in the competitive landscape.

BDTX-1535 is now the subject of a Phase 1 study.

In March, Black Diamond ​​said it would initiate IND-enabling studies for BDTX-4933 in the first quarter of the year.

.


Filed Under: clinical trials, Drug Discovery, Oncology
Tagged With: BDTX-1535, BDTX-189, BDTX-4933, Black Diamond Therapeutics, oncology
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Lab facility
Massachusetts is competing for ARPA-H biomedical research center
Blockchain
Startup vies to get blockchain adoption in pharma off the ground
Black Diamond Therapeutics
Black Diamond analysis highlights 22 new oncogenic HER2 driver mutations
NIH National Institutes of Health
NIH licenses COVID-19 research technologies to WHO initiative

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50